Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM (MIRA)
Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Type 2 Diabetes Mellitus (DM)
Sponsor: Yuhan Corporation
A PHASE4 clinical study on Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Yuhan Corporation and has accumulated 7 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Feb 2019 — Mar 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yuhan Corporation
For direct contact, visit the study record on ClinicalTrials.gov .